Results 191 to 200 of about 877,301 (350)
Computers Can Change Cardiology [PDF]
Andrew G. Wallace, Robert A. Rosati
openalex +1 more source
Trends in first‐line monotherapy and combination therapy for hypertension in UK primary care
Aims Debate remains about the optimal initial treatment strategy for hypertension. Most guidelines recommend first‐line combination therapy for most patients. However, the UK's National Institute for Health and Care Excellence recommends first‐line monotherapy for all patients.
Kyle Johnson+4 more
wiley +1 more source
Cardiovascular disease in North African women: insights from the Middle East African Women CardioVascular Disease (MEA-WCVD) registry. [PDF]
Charfeddine S+83 more
europepmc +1 more source
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr+18 more
wiley +1 more source
Correction: Impact of cardiac rehabilitation and treatment compliance after ST-segment elevation myocardial infarction (STEMI) in France, the STOP SCA+ study. [PDF]
Laurent E+10 more
europepmc +1 more source
Cardiology in the days of Laennec. The story of auscultation of the heart. [PDF]
E Bedford
openalex +1 more source
Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia
Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by platelet destruction. While most patients respond to first‐ or second‐line therapies, a small subset is multirefractory. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is a therapeutic option in these cases.
Paul Dalmas+7 more
wiley +1 more source
Optimism Model by a Cardiology Pharmacist in Breaking Bad News Among Patients with CTRCD and its Impact on Outcomes. [PDF]
Yaseen IF, Farhan HA.
europepmc +1 more source